Advanced search
Publication Cover
Clinical, Cosmetic and Investigational Dermatology Volume 17, 2024 - Issue
Submit an article Journal homepage
99
Views
0
CrossRef citations to date
0
Altmetric
CASE REPORT

A Case of Persistent Pityriasis Rosea Successfully Treated by a Short Course of Therapy with Abrocitinib

Hao WuDepartment of Dermatology, Quzhou TCM Hospital at the Junction of Four Provinces Affiliated to Zhejiang Chinese Medical University, Quzhou, People’s Republic of ChinaORCID Iconhttps://orcid.org/0009-0003-6230-662XView further author information
ORCID Icon,
Qing-Jie JiDepartment of Dermatology, Quzhou TCM Hospital at the Junction of Four Provinces Affiliated to Zhejiang Chinese Medical University, Quzhou, People’s Republic of ChinaView further author information
,
Yu-Yang XuDepartment of Dermatology, Quzhou TCM Hospital at the Junction of Four Provinces Affiliated to Zhejiang Chinese Medical University, Quzhou, People’s Republic of ChinaView further author information
&
Jian-Wei ZhuDepartment of Dermatology, Quzhou TCM Hospital at the Junction of Four Provinces Affiliated to Zhejiang Chinese Medical University, Quzhou, People’s Republic of ChinaCorrespondence[email protected]
View further author information
Pages 843-846 | Received 30 Dec 2023, Accepted 24 Mar 2024, Published online: 11 Apr 2024

References

  • Rebora A, Drago F, Broccolo F. Pityriasis rosea and herpesviruses: facts and controversies. Clin Dermatol. 2010;28(5):497–501. doi:10.1016/j.clindermatol.2010.03.005
  • Chuh AA, Chiu SS, Peiris JS. Human herpesvirus 6 and 7 DNA in peripheral blood leucocytes and plasma in patients with pityriasis rosea by polymerase chain reaction: a prospective case control study. Acta Derm Venereol. 2001;81(4):289–290. doi:10.1080/00015550152572958
  • Broccolo F, Drago F, Careddu AM, et al. Additional evidence that pityriasis rosea is associated with reactivation of human herpesvirus-6 and −7. J Invest Dermatol. 2005;124(6):1234–1240. doi:10.1111/j.0022-202X.2005.23719.x
  • Potestio L, Martora F, Cacciapuoti S, et al. Pityriasis rosea and pityriasis rosea-like eruption following COVID-19 vaccination: a narrative review. Clin Cosmet Invest Dermatol. 2024;17:51–57. eCollection 2024. doi:10.2147/CCID.S447834
  • Litchman G, Nair PA, Le JK Pityriasis rosea. Treasure Island (FL); 2022.
  • Drago F, Broccolo F, Ciccarese G, et al. Persistent pityriasis rosea: an unusual form of pityriasis rosea with persistent active HHV-6 and HHV-7 infection. Dermatology. 2015;230(1):23–26. doi:10.1159/000368352
  • González L-M, Robert A, Camila-Krysicka J, et al. Pityriasis rosea: an important papulosquamous disorder. Int J Dermatol. 2005;9:757–764. doi:10.1111/j.1365-4632.2005.02635.x
  • John-C B. An update on pityriasis rosea and other similar childhood exanthems. Curr Opin Pediatr. 2009;4:481–485. doi:10.1097/MOP.0b013e32832db96e
  • Leung A-K-C, Lam J-M, Leong K-F, et al. Pityriasis rosea: an updated review. Curr Pediatr Rev. 2021;3:201–211. doi:10.2174/1573396316666200923161330
  • Neoh C-Y, Tan A-W-H, Mohamed K, et al. Characterization of the inflammatory cell infiltrate in herald patches and fully developed eruptions of pityriasis rosea. Clin Exp Dermatol. 2009;3:300–304. doi:10.1111/j.1365-2230.2009.03469.x
  • Drago F, Vecchio F, Rebora A. Use of high-dose Acyclovir in pityriasis rosea. J Am Acad Dermatol. 2006;54(1):82–85. doi:10.1016/j.jaad.2005.06.042
  • Ganguly S. A randomized, double-blind, placebo-controlled study of efficacy of oral Acyclovir in the treatment of pityriasis rosea. J Clin Diagn Res. 2014;8(5):YC01–YC04. doi:10.7860/JCDR/2014/8140.4360
  • Das A, Sil A, Das NK, et al. Acyclovir in pityriasis rosea: an observer-blind, randomized controlled trial of effectiveness, safety and tolerability. Indian Dermatol Online J. 2015;6(3):181–184. doi:10.4103/2229-5178.156389
  • Mokadem S-A, Ghonemy S, Zidan A, et al. The role of interleukin-22 in pityriasis rosea. Clin Exp Dermatol. 2016;1:30–35. doi:10.1111/ced.12976
  • Wang S, Fu L, Du W, et al. Subsets of T lymphocytes in the lesional skin of pityriasis rosea. Anais brasileiros de dermatologia. 2019;1:52–55. doi:10.1590/abd1806-4841
  • Xia J, Jiang G. A report of eruptive pruritic papular porokeratosis treated with abrocitinib. Clin Cosmet Invest Dermatol. 2023;16:2223–2227. doi:10.2147/CCID.S424310
  • Zhang J, Zuo YG. Successful treatment of alopecia universalis with abrocitinib: a case report. J DermatolTreat. 2023;34(1):2242706. doi:10.1080/09546634.2023.2242706
  • Ren M, Yang X, Teng Y, et al. Successful treatment of granulomatous rosacea by JAK inhibitor abrocitinib: a case report. Ren Clin Cosmet Investig Dermatol. 2023;16:3369–3374. doi:10.2147/CCID.S440138
  • Teng Y, Ren M, Ding Y, et al. A case of perioral dermatitis successfully treated with abrocitinib. Clin Cosmet Invest Dermatol. 2023;16:3035–3038. doi:10.2147/CCID.S433561

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.